Related Blog Posts from the Wikinvest Wire

Amgen (AMGN)   Subscribe to Amgen (AMGN) content from the Wikinvest Wire
 » Back to Amgen (NASDAQ:AMGN) Stock Page

  

4/17/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 First Quarter Financial... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and [...]

4/4/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Provides Update On Phase 3 Study Of Talimogene La... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment [...]

3/26/14Amgen Inc (NASDAQ:AMGN) – Amgen To Webcast Investor Meeting At Upcoming American College of Car... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 26, 2014 /PRNewswire/ -- Amgen (AMGN) will host a webcast investor meeting at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14) in Washington, D.C. on Sunday, March 30, at 7 p.m. EDT. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, [...]

3/24/14Company Update (NASDAQ:AMGN): Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or [...]

3/17/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase ... (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating ... Read more on this. Amgen Inc. (AMGN), valued at $93.62B, started the session at $123.09.   Looking [...]

3/14/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Talimogene Laherparepvec Reduced Size Of Mela... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ -- Amgen (AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the body. The analysis recorded tumor-level responses [...]

3/5/14Amgen Inc (NASDAQ:AMGN) | Amgen Announces 2014 Second Quarter Dividend (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif., March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014. The dividend will ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $95.27B, started the session [...]

2/21/14Amgen Inc (NASDAQ:AMGN) – Amgen To Present At The RBC Capital Markets’ Global Healthcare Conf... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Feb. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the RBC Capital Markets' Global Healthcare Conference at 4:05 p.m. ET on Wednesday, Feb. 26, 2014, at the New York ... Read more on this. Amgen Inc. (AMGN), with a current value of $93.51B, opened this [...]

1/31/14Amgen Inc (NASDAQ:AMGN) – 2014′s Better Biotech Buy: Biogen Idec, Inc. vs. Amgen, Inc. (Jutia Group)

[at Motley Fool] - Big biotech has surged in the past few years, with Biogen and Amgen among the two leaders in this industry. Which stock looks the best for investors in 2014? Read more on this. Amgen Inc. (AMGN), valued at $90.34B, started trading this morning at $118.55.   [...]

1/30/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 30, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 ( R ed U ction of LDL-C with PCSK9 Inhibi T ion in HE te R ozygous F amilial Hyperch ... Read more on this. Amgen Inc. (AMGN), valued at $91.17B, opened at [...]

1/28/14Amgen Inc (NASDAQ:AMGN) – Amgen’s 2013 Revenues Increased 8 Percent To $18.7 Billion And Adju... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013. Key results include: For the fourth quarter, total ... Read more on this. Amgen Inc. (AMGN), valued at $91.07B, opened this morning at $118.39.   [...]

1/27/14Company Update: Amgen Inc (NASDAQ:AMGN) – Whisper Number: How Will Amgen’s Stock Move After E... (Jutia Group)

[at Wall St. Cheat Sheet] - Amgen has a 62 percent positive surprise history, having topped the whisper in 32 of the 52 earnings reports for which we have data. Read more on this. Amgen Inc. (AMGN), valued at $89.38B, started trading this morning at $119.50.   During today's session, [...]

1/24/14Amgen Inc (NASDAQ:AMGN) | Amgen: The Best Value In Biotech (Jutia Group)

[at Seeking Alpha] - The biotech industry offers investors an outsize chance to make an above average return on capital in a short period of time. The industries life blood revolves around developing cutting edge remedies ... Read more on this. Amgen Inc. (AMGN), valued at $90.22B, opened this morning at $122.59. [...]

1/23/14Amgen Inc (NASDAQ:AMGN) – What You Need to Know About Amgen’s Oncology Line-Up (Jutia Group)

[at Motley Fool] - Until recently, Amgen’s oncology presence has been somewhat limited. Over the next several years we can expect the California juggernaut to create big waves with these cancer fighting therapies. Read more on this. Amgen Inc. (AMGN), valued at $93.15B, ended session yesterday at $124.37.   Looking [...]

1/16/14Amgen, Inc. (NASDAQ:AMGN) | Will Conservative Guidance Sink This Big Biotech in 2014? (Jutia Group)

[at Motley Fool] - Celgene recently slipped on weaker-than-expected guidance for 2014. Should investors buy the dip? Let’s compare Celgene to its big biotech peers Amgen, Biogen, and Gilead Sciences, to better understand ... Read more on this. Amgen Inc. (AMGN), currently valued at $89.70B, began trading this morning at $118.82.   [...]

1/15/14Amgen, Inc. (NASDAQ:AMGN) – Mass. General, Broad Institute and Amgen Will Work to Discover New ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration ... Read more on this. Amgen Inc. (AMGN), valued at $88.87B, ended trading at $117.72.   During the trading session, [...]

1/10/14Amgen Inc. (NASDAQ:AMGN) ~ Don’t Underestimate Amgen: Part 1 (Jutia Group)

[at Seeking Alpha] - Although shares of Amgen ( AMGN ) are up over 30% this past year, many analysts and investors continue to underestimate Amgen's potential. These analysts and investors are so enthralled by the immediate ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $89.30B, ended [...]

1/9/14Amgen Inc. (NASDAQ:AMGN) ~ Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Ap... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Jonathan M. Peacock, executive vice president and chief financial officer, is leaving Amgen to pursue broader ... Read more on this. Amgen Inc. (AMGN), with a current value of $89.66B, opened this morning at $116.54.   [...]

1/6/14Stock Update: The Walt Disney Company (NYSE:DIS) – Dividend Portfolio Playoffs Wild Card Game: ... (Jutia Group)

[at Seeking Alpha] - In the first round of the Dividend Portfolio playoffs we have #12 seeded Amgen, Inc. ( AMGN ) taking on #5 seeded Walt Disney Company ( DIS ). Amgen is a global biotech company that discovers, develops, ... Read more on this. The Walt Disney Company (DIS), with a [...]

1/6/14Amgen Inc. (NASDAQ:AMGN) – Dividend Portfolio Playoffs Wild Card Game: Amgen Vs. Disney (Jutia Group)

[at Seeking Alpha] - In the first round of the Dividend Portfolio playoffs we have #12 seeded Amgen, Inc. ( AMGN ) taking on #5 seeded Walt Disney Company ( DIS ). Amgen is a global biotech company that discovers, develops, ... Read more on this. Amgen Inc. (AMGN), valued at $86.09B, started [...]

1/2/14Company Update – Amgen Inc. (NASDAQ:AMGN) – Gilead Sciences: Sovaldi to Boost Shares in 2014,... (Jutia Group)

[at Barrons.com] - Maxim Group's Jason Kolbert upped his target for Gilead Sciences (GILD) today, based on potential sales of Sovaldi. Shares of Gilead gained 104% in 2013, besting Amgen's (AMGN) 35% rise, Regeneron Pharmaceuticals (REGN) ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $87.31B, opened at [...]

12/19/13Amgen Inc. (NASDAQ:AMGN) – Amgen cholesterol drug succeeds in late-stage trial (Jutia Group)

[Reuters] - Amgen Inc said its closely watched experimental cholesterol drug succeeded in reducing the level of bad cholesterol in the blood, compared to a placebo, in a late-stage trial. The data was consistent with the results from a large mid-stage trial that showed the drug, evolocumab, lowered LDL cholesterol by 52 percent after [...]

12/17/13Amgen Inc. (NASDAQ:AMGN) ~ Amgen announces MENDEL-2 Phase 3 trial met co-primary endpoints (Jutia Group)

[theflyonthewall.com] - Amgen announced that the Phase 3 MENDEL-2 trial with evolocumab met its co-primary endpoints, which was the percent reduction from baseline in low-density lipoprotein cholesterol at week 12 and the mean ... Read more on this. Amgen Inc. (AMGN), with a current value of $83.20B, started the session at $112.86. [...]

12/16/13Company Update – Amgen Inc. (NASDAQ:AMGN) – How To YieldBoost Amgen To 4.1% Using Options (Jutia Group)

[at Forbes] - Shareholders of Amgen (NASD: AMGN) looking to boost their income beyond the stock's 1.7% annualized dividend yield can sell the January 2016 covered call at the $150 strike and collect the premium based on the $5.65 bid, which annualizes to an additional 2.4% rate of return against the current stock [...] [...]

12/13/13Stock Update: Amgen Inc. (NASDAQ:AMGN) – Amgen Announces 2014 First Quarter Dividend (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 13, 2013 /PRNewswire/ -- Amgen (AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the first quarter of 2014. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative [...]

12/10/13Amgen Inc. (NASDAQ:AMGN) – Amgen To Host Post American Society of Hematology (ASH) Summary Webcast (Jutia Group)

THOUSAND OAKS, Calif., Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president [...]

12/6/13Amgen Inc. (NASDAQ:AMGN) – The International Myeloma Foundation Announces Partnership With Onyx... (Jutia Group)

[Marketwired] - The International Myeloma Foundation -- improving the quality of life of myeloma patients while working toward prevention and a cure -- and Onyx Pharmaceuticals, Inc., an Amgen subsidiary , today announced ... Read more on this. Amgen Inc. (AMGN), currently valued at $86.05B, opened at $115.00.   Looking [...]

12/5/13Amgen Inc. (NASDAQ:AMGN) – Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 5, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate at the Oppenheimer 24 th Annual Healthcare Conference on Tuesday, Dec. 10, 2013, at the Crowne Plaza in New York ... Read more on this. Amgen Inc. (AMGN), with a current value of $85.48B, began trading this morning [...]

11/22/13Company Update – Amgen Inc. (NASDAQ:AMGN) – I’m Staying Away From Low Yielding Amgen For Now (Jutia Group)

[at Seeking Alpha] - The last time I wrote about Amgen ( AMGN ) I bought a small batch in it stating that was a good value at the time. Since the last article it actually shot up 7% excluding the dividend (it is up 7.41% including ... Read more on this. Amgen [...]

11/20/13Company Update: Amgen Inc. (NASDAQ:AMGN) – Ahead of the Bell: Amgen’s cholesterol drug (Jutia Group)

[AP] - Amgen said Tuesday that an experimental drug reduced patients' "bad" cholesterol levels by half in a yearlong study. The company said patients who took the drug, called evolocumab, and standard ... Read more on this. Amgen Inc. (AMGN), valued at $87.37B, opened at $115.36. During the trading session, AMGN [...]

11/14/13Biogen Idec Inc. (NASDAQ:BIIB) | Better Buy: Biogen or Amgen? (Jutia Group)

[at Motley Fool] - Both Biogen and Amgen are fighting competition with new drugs with blockbuster potential, but is one a better buy than the other? Read more on this. Biogen Idec Inc. (BIIB), with a current value of $56.39B, started the session at $237.91. Looking at today's market, BIIB one [...]

11/14/13Company Update – Amgen Inc. (NASDAQ:AMGN) – Better Buy: Biogen or Amgen? (Jutia Group)

[at Motley Fool] - Both Biogen and Amgen are fighting competition with new drugs with blockbuster potential, but is one a better buy than the other? Read more on this. Amgen Inc. (AMGN), currently valued at $87.40B, started trading this morning at $114.02. A quick look at the market, the company's [...]

11/12/13Amgen Inc. (NASDAQ:AMGN) – Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming America... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 12, 2013 /PRNewswire/ -- Amgen (AMGN) today announced that it will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood1, at [...]

11/7/13Stock Update: Amgen Inc. (NASDAQ:AMGN) – Amgen Foundation Commits $2.5 Million In New Grants To... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 7, 2013 /PRNewswire/ -- The Amgen Foundation today announced $2.5 million in new grants for the Amgen Biotech Experience, an innovative science education program, bringing the total committed to nearly $8 million since the program's inception in 1990. The Amgen Biotech Experience provides a real-world biotech lab [...]

10/25/13Company Update: Amgen Inc. (NASDAQ:AMGN) – Amgen Reports Strong Numbers, But Better Days May Be... (Jutia Group)

[at Motley Fool] - Amgen saw rapid growth for Xgeva and Prolia in the third quarter, but future growth may be driven by Asian partnerships, new drugs, and Amgen's acquisition of Onyx Pharmaceuticals. Read more on this. Amgen Inc. (AMGN), valued at $87.40B, started trading this morning at $116.50. During the trading session, AMGN [...]

10/24/13Can AbbVie Hold Off Amgen and Pfizer? – AbbVie Inc. (NYSE:ABBV) (Jutia Group)

[at Motley Fool] - AbbVie has relied on Humira for rheumatoid arthritis for years, but with its patent expiring within three years, AbbVie will have to find answers to go up against the longer-lived patent protection that ... Read more on this. AbbVie Inc. (ABBV), valued at $76.20B, began trading this morning at $48.63. [...]

10/24/13Market Update on Amgen Inc. (NASDAQ:AMGN) – Celgene’s New Multiple Myeloma Drug Is Kicking Am... (Jutia Group)

[at TheStreet] - CELG data by YCharts SUMMIT, NJ ( TheStreet ) -- Celgene issued another "beat and raise" earnings report for the third quarter earnings -- pretty much standard operating procedure these days ... Read more on this. Amgen Inc. (AMGN), with a current value of $88.07B, started trading this morning at $116.28. [...]

10/23/13Company Update: Amgen Inc. (NASDAQ:AMGN) – Amgen – Trading Around All-Time Highs As It Shifts... (Jutia Group)

[at Seeking Alpha] - Shares of Amgen ( AMGN ) set fresh all time highs on Tuesday after the biotechnology company reported a solid set of third quarter results. Amgen was furthermore upbeat about the integration with Onyx ... Read more on this. Amgen Inc. (AMGN), valued at $87.00B, opened this morning at $114.94. [...]

10/22/13Market Update on Amgen Inc. (NASDAQ:AMGN) – Amgen Acquires Filgrastim Franchise Rights From Roc... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ("Roche") to acquire Roche's ... Read more on this. Amgen Inc. (AMGN), valued at $86.04B, opened at $114.38. Looking at the equity, the company's one day range [...]

8/27/13Biotech Cancer Investing (Energy and Capital)

In one of the biggest deals in recent biotech history, Amgen (NASDAQ: AMGN) will purchase Onyx Pharmaceuticals (NASDAQ: ONXX) for $10.4 billion...

3/22/13Amgen (NASDAQ:AMGN) Soars on Cancer Therapy Test (Wealth Daily)

Biotech company Amgen (NASDAQ:AMGN) received a huge boost after promising results in the test of its melanoma tumor-reducing vaccine...

2/27/13(AMGN) The Picks and Shovels (and Levi’s) of Biotech (Stock Blog Hub)

Yesterday marked the 184th birthday of an iconic American businessman – Levi Strauss My wife worked for Levi Strauss & Co. many years ago. They were a terrific company, with a strong commitment to product quality, their employees and their community. I was so impressed that I remain loyal and almost exclusively buy Levi’s when I [...]

1/23/13Amgen’s Dividend Policy Has Ignited Their Stock (The DIV-Net)

Founded in 1980, Amgen (AMGN) is the world’s largest biotechnology company with a current market cap of just under $68 billion.  However, in spite of its already large size, we believe that Amgen has ample room to continue growing their earnings at above-average rates into the foreseeable future.  Our optimism for future growth is predicated on several factors.  First and foremost, Amgen has a strong pipeline of potential blockbuster medicines, many of which are already in Phase...

1/9/13Biotech Collaborates with Startup on Cancer Drug (Wealth Daily)

Major biotech Amgen (NASDAQ: AMGN) is working with a startup to create a drug targeting cancer cells.

12/25/12UPDATE: Amgen Raises Qtr. Dividend from $0.36 to $0.47/Share, Adds $2B to Buyback Plan (Phil’s Stock World)

Courtesy of Benzinga. Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013. The dividend will be paid on March 7, 2013, to all stockholders of record as of the close of business on Feb. 13, 2013. This represents an [...]

12/20/12Biotech Sued for Off-Label Marketing (Wealth Daily)

Amgen's (NASDAQ: AMGN) was approved for specific uses by the FDA, but the company marketed its drug for other things, too.

12/12/12Biotech Buys Genetic Disease Research Firm (Wealth Daily)

Biotech leader Amgen Inc. (NASDAQ: AMGN) has agreed to purchase deCODE Genetics, a company that can help improve drug research.

8/24/12(AMGN) Amgen Suffers Pipeline Setback (Stock Blog Hub)

Amgen (AMGN) recently suffered a pipeline setback with the company deciding to halt the development of its oncology candidate, ganitumab (AMG 479).The decision was based on the recommendation of an independent Data Monitoring Committee (DMC). The randomized, multicenter, double-blind, phase III study (GAMMA) evaluated whether the combination of AMG479 and Eli Lilly’s (LLY) Gemzar improved overall [...]

8/20/12(AMGN) Amgen Beats The Street – Raises Guidance (Stock Blog Hub)

Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents above the Zacks Consensus Estimate and 34.8% above the year-ago period. Higher revenues and a lower share count contributed to the year-over-year increase in earnings. Total revenue increased 13% to $4,477 million in the second quarter [...]

2/27/12Investing in Innovative Human Therapeutics Called Biotech (Invest2Success)

Click Here for Help on Finding Stocks to Buy and Sell I’ve got a low-risk high-reward buy long stock pick this week on biotech giant Amgen. I’m still thinking the market needs a much needed correction but it seems is not full-on short sell time just yet. Then again, maybe it happens this week. In any event there’s always some quality stocks with potential upside appreciation to trade and or invest in any market. Lets hope Amgen is one of those this week going forward. As a possible...


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki